Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 305

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: A randomized trial

Open access
Hsu, Chiun, Hsiung, Chao A., Su, Ih-Jen, Hwang, Wei-Shou, Wang, Ming-Chung, Lin, Sheng-Fung, Lin, Tseng-Hsi, Hsiao, Hui-Hua, Young, Ji-Hsiung, Chang, Ming-Chih, Liao, Yu-Min, Li, Chi-Cheng, Wu, Hung-Bo, Tien, Hwei-Fang, Chao, Tsu-Yi, Liu, Tsang-Wu, Cheng, Ann-Lii, Chen, Pei-Jer·2008·Hepatology
DOI 10.1002/hep.22106
Open this paper in CoChat — free account

Abstract

Lamivudine is effective to control hepatitis B virus (HBV) reactivation in HBV-carrying cancer patients who undergo chemotherapy, but the optimal treatment protocol remains undetermined. In this study, HBV carriers with newly diagnosed non-Hodgkin's lymphoma (NHL) who underwent chemotherapy were randomized to either prophylactic (P) or therapeutic (T) lamivudine treatment groups. Group P patients started lamivudine from day 1 of the first course of chemotherapy and continued treatment until 2 months after completion of chemotherapy. Group T patients received chemotherapy alone and started lamivudine treatment only if serum alanine aminotransferase (ALT) levels elevated to greater than 1.5-fold of the upper normal limit (ULN). The primary endpoint was incidence of HBV reactivation during the 12 months after starting chemotherapy. During chemotherapy, fewer group P patients had HBV reactivation (11.5% versus 56%, P = 0.001), HBV-related hepatitis (7.7% versus 48%, P = 0.001), or severe hepatitis (ALT more than 10-fold ULN) (0 versus 36%, P < 0.001). No hepatitis-related deaths occurred during protocol treatment. Prophylactic lamivudine use was the only independent predictor of HBV reactivation. After completion of chemotherapy, the incidence of HBV reactivation did not differ between the 2 groups. Two patients, both in group P, died of HBV reactivation–related hepatitis, 173 and 182 days, respectively, after completion of protocol treatment. When compared with an equivalent group of lamivudine-naïve lymphoma patients who underwent chemotherapy, therapeutic use of lamivudine neither reduced the severity of HBV-related hepatitis nor changed the patterns of HBV reactivation. Conclusion: Prophylactic lamivudine use, but not therapeutic use, reduces the incidence and severity of chemotherapy-related HBV reactivation in NHL patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.22106

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 305

Metadata

Authors
Hsu, C., Hsiung, C. A., Su, I.-J., Hwang, W.-S., Wang, M.-C., Lin, S.-F., Lin, T.-H., Hsiao, H.-H., Young, J.-H., Chang, M.-C., Liao, Y.-M., Li, C.-C., Wu, H.-B., Tien, H.-F., Chao, T.-Y., Liu, T.-W., Cheng, A.-L., & Chen, P.-J.
Venue
Hepatology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2008-03
Volume
47
Issue
3
Pages
844-853
ISSN
0270-9139 (ISSN-L)
DOI
10.1002/hep.22106
OpenAlex
W2164785014
Cited by
305
References
18
FWCI
15.77
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: A randomized trial. https://app.cochat.ai/papers/10.1002/hep.22106
The paper
Hsu, C., Hsiung, C. A., Su, I.-J., Hwang, W.-S., Wang, M.-C., Lin, S.-F., Lin, T.-H., Hsiao, H.-H., Young, J.-H., Chang, M.-C., Liao, Y.-M., Li, C.-C., Wu, H.-B., Tien, H.-F., Chao, T.-Y., Liu, T.-W., Cheng, A.-L., & Chen, P.-J. (2008). A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: A randomized trial. Hepatology. https://doi.org/10.1002/hep.22106

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.